Amneal Pharmaceuticals

What Amneal Pharmaceuticals does

Amneal Pharmaceuticals, Inc. is a publicly traded U.S. pharmaceutical company (NASDAQ: AMRX) headquartered in Bridgewater, New Jersey, founded in 2002 by brothers Chirag and Chintu Patel. The company operates three reporting segments: Affordable Medicines (complex generics, injectables, and biosimilars spanning oral solids, ophthalmics, inhalation, topicals, transdermals, and nasal sprays); Specialty (branded CNS and endocrine products including CREXONT for Parkinson's disease and Brekiya for migraine and cluster headaches); and AvKARE (pharmaceutical distribution to U.S. federal government, retail, and institutional customers).

The company's technology foundation rests on proprietary drug delivery platforms including GRANDE® and KRONOTEC® for extended-release formulations, plus a novel mucoadhesive polymer technology used in CREXONT that delivers the longest-lasting levodopa plasma levels among oral carbidopa/levodopa therapies. Amneal operates approximately 1 million square feet of advanced U.S. manufacturing space in Brookhaven, NY, plus manufacturing operations in India (Ahmedabad, Vizag, Rajoda) and Ireland, supported by a global Quality organization of roughly 1,700 employees that has cleared 115+ regulatory inspections over 23 years.

Amneal generates revenue through product sales across 290+ medicines delivering 160+ million prescriptions annually. FY2025 net revenue was $3.02 billion (up 8% YoY) with FY2026 guidance of $3.05–$3.15 billion. Its go-to-market combines a direct field sales force, specialty pharmacy partnerships (Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy), U.S. wholesale distribution for generics, and direct federal distribution via the wholly-owned AvKARE subsidiary. Strategic partnerships include mAbxience for biosimilar development and commercialization (denosumab biosimilars Boncresa and Oziltus), KeifeRx for Parkinson's research collaboration, and a pending $1.1 billion acquisition of Kashiv BioSciences to build a fully integrated global biosimilars platform expected to close in H2 2026.

Name

Amneal Pharmaceuticals

Legal name

Amneal Pharmaceuticals, Inc.

Website

https://amneal.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Amneal Pharmaceuticals is a publicly traded U.S. biopharmaceutical company operating three segments: Affordable Medicines (generics, biosimilars, injectables), Specialty (branded CNS/endocrine therapies such as CREXONT and Brekiya), and AvKARE federal/institutional distribution, delivering 160+ million prescriptions annually across 290+ products.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Ophthalmic Goods (3851)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Generic pharmaceuticals
• Specialty medicines
• Biosimilar products
• Injectable manufacturing
• Pharmaceutical distribution

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Affordable Medicines Segment: Revenue from generic pharmaceuticals including complex formulations, injectables, and biosimilars. This is the largest segment, covering retail and institutional products delivered through wholesalers and direct distribution.
2. Specialty Segment: Revenue from branded pharmaceutical products focused on central nervous system (Parkinson's disease, migraine, cluster headache) and endocrine disorders. Commercialized through field sales force and specialty pharmacies.
3. AvKARE Segment: Distribution of pharmaceuticals and medical products to U.S. federal government, retail, and institutional customers.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Amneal Pharmaceuticals develops, manufactures, and commercializes generic pharmaceuticals, specialty branded medicines, and biosimilars across three segments: Affordable Medicines (complex generics, injectables, ophthalmics, inhalation products), Specialty (CNS and endocrine branded therapies for Parkinson's disease, migraine, cluster headache, and hypothyroidism), and AvKARE (pharmaceutical distribution to U.S. federal government, retail, and institutional markets). The company operates approximately 1 million square feet of advanced U.S. manufacturing space and delivers over 160 million prescriptions annually across its 290+ product portfolio.

Product overview

Amneal Pharmaceuticals operates as a diversified global biopharmaceutical company with three primary business segments: Affordable Medicines (generic and biosimilar products), Specialty (branded CNS and endocrine products), and AvKARE (pharmaceutical distribution). The Affordable Medicines segment includes over 270 generic medicines spanning complex formulations across oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, with key products including Beclomethasone Dipropionate HFA, epinephrine auto-injectors, and naloxone nasal spray. The Specialty segment features branded products including CREXONT (Parkinson's disease), Brekiya (migraine/cluster headache), RYTARY, UNITHROID, and ONGENTYS. The Biosciences portfolio includes biosimilar products FYLNETRA, ALYMSYS, Boncresa, and Oziltus, along with specialty injectables like Boruzu and PEMRYDI RTU. The company delivers over 160 million prescriptions annually across the U.S. market.

Differentiator

Problem solved

Functional benefit

Brands

• Amneal Biosciences: Delivers growing portfolio of biosimilars and specialty injectable products
• AvKARE
• CREXONT
• Brekiya
• PATHways
• Boruzu
• UNITHROID
• RYTARY
• ONGENTYS
• EMVERM
• ALYMSYS
• FYLNETRA

Products and services

• CREXONT (carbidopa and levodopa) Innovative extended-release oral formulation for Parkinson's disease combining immediate-release granules for rapid onset with extended-release pellets for long-lasting efficacy, providing longer Good On time with less frequent dosing.
• Brekiya (dihydroergotamine mesylate) First and only ready-to-use dihydroergotamine (DHE) autoinjector approved for acute treatment of migraine with or without aura and acute treatment of cluster headaches in adults.
• RYTARY (carbidopa and levodopa) Extended-release capsules for treatment of Parkinson's disease, providing continuous levodopa delivery.
• ONGENTYS (opicapone) Capsules for treatment of Parkinson's disease as adjunct therapy to levodopa/carbidopa.
• UNITHROID (levothyroxine sodium) Oral prescription medicine for hypothyroidism, providing thyroid hormone replacement.
• EMVERM (mebendazole) Anthelmintic medication for treatment of worm infections including whipworm, hookworm, and pinworm.
• FYLBAR (filgrastim biosimilar) Biosimilar referencing Neupogen for chemotherapy-induced neutropenia support.
• FYLNETRA (pegfilgrastim biosimilar) Biosimilar to Amgen's Neulasta for reducing infection incidence in patients receiving myelosuppressive chemotherapy.
• ALYMSYS (bevacizumab biosimilar) Biosimilar referencing Avastin for treatment of various cancers including metastatic colorectal cancer, non-small cell lung cancer, and renal cell carcinoma.
• Boncresa (denosumab biosimilar) Biosimilar referencing Amgen's Prolia for osteoporosis treatment and bone loss prevention.
• Oziltus (denosumab biosimilar) Biosimilar referencing Amgen's XGEVA for prevention of skeletal-related events in cancer patients with bone metastases.
• Boruzu (generic bortezomib) Generic oncology injectable product for multiple myeloma treatment.
• PEMRYDI RTU Ready-to-use oncology injectable developed via 505(b)(2) pathway, designed to simplify storage and preparation.
• Beclomethasone Dipropionate HFA Inhalation Aerosol FDA-approved generic equivalent for QVAR, available in 40 mcg and 80 mcg doses for asthma maintenance therapy in patients 5 years and older.
• Epinephrine Auto-injector Auto-injector for emergency treatment of anaphylaxis.
• Naloxone HCl Nasal Spray Opioid overdose reversal medication.
• Albuterol Sulfate Inhalation Aerosol Generic version of PROAIR HFA for treatment of bronchospasm.
• Cyclosporine Ophthalmic Emulsion 0.05% Generic version of RESTASIS for dry eye disease by increasing tear production.
• Iohexol Injection Contrast agent for various imaging procedures including CT scans.
• Romidepsin Injection Ready-to-use formulation for treating cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy.
• PATHways Patient Support Program Comprehensive patient and provider support program offering co-pay assistance, patient assistance, and treatment access support services.
• AvKARE Distribution Services Distributor of pharmaceuticals and other products for U.S. federal government, retail, and institutional markets.

Quantifiable outcome

• 160+ million prescriptions delivered annually
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered flagship, strategic and core.

• Kashiv BioSciencesflagshipStrategic or Co-development Partner · 22 April 2026Definitive agreement for Amneal to acquire Kashiv BioSciences for $375M cash, $375M equity at closing, plus up to $350M in milestones (total $1.1B). The acquisition creates a fully integrated global biosimilars platform combining Kashiv's R&D, manufacturing, and regulatory capabilities with Amneal's commercial scale. Expected to close H2 2026 pending shareholder and regulatory approvals.
• KeifeRxstrategicStrategic or Co-development Partner · 9 January 2026Research collaboration and option agreement to advance pre-IND development of KFRX06, a preclinical candidate targeting Parkinson's disease based on KeifeRx's LRRK2 inhibitor technology. Collaboration establishes a structured path for potential next-stage development and commercialization.
• mAbxiencecoreStrategic or Co-development Partner · 22 December 2025Partnership for development and manufacturing of biosimilars. Amneal holds exclusive U.S. commercialization rights for jointly developed biosimilars including Boncresa and Oziltus (denosumab biosimilars referencing Prolia and XGEVA). mAbxience handles development and manufacturing while Amneal commercializes in the U.S.
• Saol TherapeuticsstrategicStrategic or Co-development Partner · 5 January 2022Acquisition of Saol Therapeutics' Baclofen franchise including Lioresal and LYVISPAH products valued at approximately $83.5 million. Transaction aimed to expand Amneal's neurology portfolio and enhance biosimilar market entry.
• Puniska HealthcarestrategicStrategic or Co-development Partner · 10 November 2021Acquisition of Indian injectable drug manufacturer Puniska Healthcare for Rs 700 crore. Transaction expanded Amneal's injectable manufacturing capacity in the U.S. and globally, including India. Facility in Ahmedabad was prepared for USFDA inspection.
• Dispensary of HopecoreStrategic or Co-development PartnerTwelve-year partnership with Nashville-based nonprofit distributing medicines to pharmacies and safety-net clinics for low-income, chronically ill patients. Amneal has donated more than 20 million dosages through this partnership, touching hundreds of thousands of lives across the U.S.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Teva Pharmaceutical Industries: Largest U.S. generics manufacturer with a global specialty franchise (CNS, respiratory) and biosimilars pipeline. Direct head-to-head competitor with Amneal in U.S. generics and CNS specialty, including Parkinson's disease products; Amneal's former CCO (Andy Boyer) and Chief Legal Officer (Jason Daly) both came from Teva, underscoring competitive overlap.
• Viatris: Global generics and specialty pharma formed from Mylan and Upjohn. Competes directly with Amneal across U.S. generics, biosimilars, and select specialty categories, and is similarly exposed to U.S. generic pricing pressure and biosimilar launch cycles.
• Sandoz (Novartis): Global leader in generics and biosimilars, now independent from Novartis. Competes directly with Amneal's Affordable Medicines and Biosciences segments, especially in biosimilars (denosumab, pegfilgrastim, bevacizumab) where Amneal is also launching. Jeff George (Amneal director) was previously CEO of Sandoz.
• Hikma Pharmaceuticals: U.S./MENA generics and injectables manufacturer with a growing specialty franchise. Overlaps with Amneal's generics, injectables, and increasingly specialty footprint, including respiratory and CNS categories.
• Dr. Reddy's Laboratories: India-based global generics and biosimilars company with substantial U.S. presence. Competes with Amneal in complex generics, injectables, and biosimilars and shares a similar India-plus-US manufacturing cost structure.
• Sun Pharmaceutical Industries: India's largest specialty pharma company with a significant U.S. generics and specialty business (including CNS). Overlaps directly with Amneal's generic portfolio and U.S. specialty ambitions, particularly in neurology.
• Aurobindo Pharma: Indian-headquartered global generics and biosimilars manufacturer with strong U.S. share. Competes with Amneal across oral solids, injectables, and biosimilars, including respiratory and CNS categories.
• Lupin Pharmaceuticals: India-based global pharma with a U.S. generics and specialty franchise (CNS, respiratory, women's health). Direct competitor with Amneal in U.S. complex generics and emerging biosimilars.

Emerging players

• Endo International: U.S. specialty and generics pharma with focus on neurology, pain, and ophthalmology. Overlaps with Amneal's specialty portfolio in CNS/neurology and shares exposure to U.S. specialty launch dynamics.

Regional players

• Zydus Lifesciences: India-based pharma with U.S. generics, injectables, and biosimilars business. Comparable to Amneal in manufacturing footprint and product mix; competes most directly in U.S. generics and biosimilars and shares similar India supply-chain dynamics. Several Amneal R&D and quality leaders previously worked at Zydus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/amnealpharma
• YouTubeyoutube.com/channel/UCQ1VlP0GTdfiL_WrJzIlzOQ
• Facebookfacebook.com/people/Amneal-Pharmaceuticals/100076381024161
• LinkedInlinkedin.com/company/amneal-pharmaceuticals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amneal Pharmaceuticals